Warren RB, Reich K, Simpson EL, Langley R, Costanzo A, Saeki H, Almgren P, Vacko E, Gooderham M, Deleuran M, Francisco Silvestre J, Weidinger S, Blauvelt A. 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. J of Skin [Internet]. 2022Nov.16 [cited 2024Sep.20];6(6):s78. Available from: https://dermsquared.com/skin/article/view/1836